Other Transaction Agreement HR00112090121

Award Date 9/17/20
Potential Completion Date 8/16/21
Potential Value $454K
Ultimate Awardee
Not listed
NAICS Category
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed
Major Defense Program
Not listed
Pricing Type
Other
Place of Performance
Burlingame, CA 94010, USA
Solicitation Procedures
Broad Agency Announcement
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $999,923 Small Business Innovation Research (SBIR) Phase II contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Inflammatix, Inc., a small disadvantaged business in Sunnyvale, California. The contract is for the development of point-of-care diagnostic solutions to monitor the host-pathogen interaction during infection. Inflammatix has been awarded over $29 million in federal contracts and grants from agencies like the Department of Health and Human Services and...
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a $27,992,718.00 definitive contract to Inflammatix, Inc., a self-certified small disadvantaged business organization, for the development of "a full stack of host-response solutions to infectious disease testing to address outpatient and inpatient testing for acute infections and sepsis both during and outside of influenza season." This contract, which has a...
This federal contract award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Inflammatix, Inc., a small disadvantaged business. The $749,999 firm fixed-price contract supports research and development for the Triverity cartridge, a diagnostic tool focused on infection severity and sepsis detection, under Area of Interest #2 of ASPR's Easy Broad Agency Announcement. The...
This federal contract award, valued at $749,549.00, was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Immunexpress Inc., a for-profit foreign-owned company. The contract is for the "ASSESSMENT & TRIAGE OF PATIENTS WITH ESCALATING SIGNS OF COVID-19 DISEASE USING A HOST RESPONSE TEST FOR SEPSIS" and is a definitive, firm-fixed-price contract with a period of performance ending on June 10, 2023. The contract award originated from a Broad...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Mbio Diagnostics Inc., doing business as Lightdeck Diagnostics, for the development of a "Point of Care Host-Pathogen Monitoring System." The fixed-price contract has a ceiling value of $149,503.39 and was awarded on November 18, 2016, with a completion date of November 27, 2017. Mbio Diagnostics Inc. is a for-profit organization that develops...
This $34,714,763.00 cost-plus-fixed-fee contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Detect Inc. to advance the development of a second-generation, multi-analyte molecular SARS-CoV-2 and influenza A/B test that has a reduced time to result and increased sensitivity for use at home or in a point-of-care setting. The contract is not set aside. The award references a Broad Agency Announcement (BAA) issued by the Biomedical Advanced Research...
This is a $12,670,301.06 firm fixed-price definitive contract awarded by the U.S. Department of Health and Human Services (DHHS) Biomedical Advanced Research and Development Authority (BARDA) to Inbios International, Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract is for the production capacity expansion of COVID-19 diagnostic tests and was awarded under Contracting Opportunity FA7013-20-S-0002, which did not have a set-aside designation....
This is a $749,000.00 firm fixed price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian federal agency, to In Diagnostics, Inc. to develop endpoint and kinetic measurement capabilities on a low-cost, disposable spectrophotometer platform. The contract does not have a set-aside designation and is scheduled for completion by June 30, 2025. The awardee, In Diagnostics, Inc., is a for-profit organization located in Carlsbad, California.
<p>The U.S. Defense Advanced Research Projects Agency (DARPA) awarded a Firm Fixed Price, Definitive Contract to Probiusdx Inc., a small business, for point-of-care monitoring of the host-pathogen interaction during infection. The contract has a ceiling value of $1,746,921.00 and a period of performance ending on November 15, 2021. This contract was awarded under DARPA's SBIR (Small Business Innovation Research) Program Phase II. The place of performance is Duncans Mills, CA.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the Defense Health Agency (DHA) to Firebird Biomolecular Sciences LLC, a for-profit limited liability company, for the development of &quot;Innovative DNA for Highly Multiplexed Molecular Diagnostics&quot;. The $249,956.88 firm-fixed-price contract has a period of performance ending on May 8, 2025. The contract supports research and development of novel molecular technologies to create a rapid, point-of-sampling...

This contract was awarded by the Defense Advanced Research Projects Agency (DARPA) to Inflammatix, Inc., a small disadvantaged business, for the development of a host-response prognostic tool called HOSTDXTM-COVID SEVERITY. The $453,851.00 contract is for research, development, and testing services related to diagnostic solutions for COVID-19 and other viral pandemics. Inflammatix has received over $29 million in federal contracts and grants from the Department of Health and Human Services to support the development of diagnostic cartridges and host-response prognostic tools, including for sepsis and inflammatory bowel disease. This contract does not have a set-aside designation.

Generated 3/23/24, 1:41 PM